CD4 and myeloid sarcoma: The analysis of patients between the relapse and remission phases revealed significantly decreased percentages of CD4+CXCR3+ Th1 cells (P = 0.038) and CD8+CXCR3+ Tc1 cells (P = 0.023) at the remission phase in all 5 MS patients (Figure 1).